Understanding mTNBC - Metastatic Triple-Negative Breast Cancer


 

Key Takeaways:

  • TNBC accounts for approximately 10% to 15% of all existing breast cancers.
  • The majority of cases of Triple-Negative Breast Cancer are diagnosed in women aged 51 to 60 years.
  • Triple-Negative Breast Cancer more commonly affects African American and Hispanic women.
  • Breast cancer linked with a BRCA-1/BRCA-2 mutation is often, but not always, triple negative.

mTNBC and Other Types of Breast Cancer:

Different types of breast cancer are grouped by whether or not the cancerous cells have certain protein-named receptors. Cancerous cells typically may have a couple of types of hormones (either estrogen or progesterone) or another receptor named HER2. 

If cancerous cells have (or are +Ve for)these receptors, they can be treated with therapies that are mainly designed to target those receptors or that result in making fewer hormones.

But metastatic triple-negative breast cancer cells are negative for estrogen receptors (ER), progesterone receptors (PR), and HER2, which typically means they tested negative for ER, PR, and HER2, hence the name triple-negative breast cancer (TNBC). 

Without these three receptors, treatment for metastatic triple-negative breast cancer is more limited than other sorts of breast cancer and may need a different outlook.

Treatment for metastatic Triple-Negative Breast Cancer (mTNBC):

There is a medicine in the town named Trodelvy, which is the only Metastatic Triple-Negative Breast cancer drug of its kind. Unlike some other medicines, Trodelvy 180 mg does not need unhealthy cells to have ER, PR, or HER2 to work, which is why the medicinal product is a potential option for those with metastatic triple-negative breast cancer.

Rather, the medicine Trodelvy is designed to seek out a different protein that may exist on breast cancer cells, including those found in metastatic triple-negative breast cancer.

Buy Trodelvy from The Indian Pharma:

Trodelvy injection price in India is low and can vary. If you are looking to procure/buy Trodelvy injections hassle-free at a reasonable price from India, then we can be your one-stop solution. Kindly get in touch with us through TOLL-FREE Number: 1800-889-1064. We are a WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Exporter/ Importer and Supplier of Trodelvy sacituzumab govitecan-hziy 180 mg/200 mg from India.

Reference:

https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy

Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b
Read more

Trodelvy: All about the drug

Image
Indication and Usage The medicine Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate drug, which is used in the treatment of adults suffering from locally advanced or metastatic triple-negative breast (mTNBC) cancer, HR+/HER2- metastatic breast cancer, and locally advanced or metastatic urothelial cancer (mUC). It is used when it is not possible to remove cancer with surgery. Trodelvy  comes in the form of single-dose vials in 180 mg for intravenous infusion. Dosage Its dosage is based on body weight, and the recommended dosage is 10 mg/kg administered intravenously once weekly on the first day and eighth day of a repeating 21-day cycle. Administration First infusion: The drug is infused in the body for 3 hours, and during the infusion, the patient is observed for any adverse reaction caused by the infusion. After 30 minutes of infusion, observation should be done again to check for any post-infusion reaction. Subsequent Infusion: If the drug is tolerated in t
Read more

What is Non-Small Cell Lung Cancer? What are the stages of NSCLC?

Image
NSCLC, the most common form of lung cancer. It occurs when the healthy cells in the lung change and start growing in an abnormal way, forming a specific mass addressed as tumor, lesion, or nodule. A tumor may develop anywhere in the lung and could be cancerous or benign. A cancerous tumor mainly is malignant, means, it has potential in order to spread to the rest part of the body. A benign tumor is the tumor that can grow but can not spread.  Non-Small Cell Lung Cancer (NSCLC) occurs in the epithelial cells. Doctors can also describe this form of Cancer (NSCLC) based on the type of the epithelial cell where the cancer usually starts.  Adenocarcinoma starts in cells that produce mucus.  Squamous carcinoma basically developed in the cells that line the airways.  Large cell carcinoma usually begins in the cells other than the two types which are described above.  It’s necessary for healthcare providers to distinguish between lung cancer that begins in the squamous cells from lung cancer
Read more